Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory ...

Full Year Financial Results 2024 - a pivotal year marking the transition from developer to producer at our flagship Nalunaq mine TORONTO, ONTARIO – 28 March 2025 – Amaroq Minerals Ltd. (AIM, TSX-V, ...

Olverembatinib (HQP1351), a novel, next-generation TKI and the first third-generation BCR-ABL1 TKI, has been approved in ...

The company’s latest results mark a dramatic turnaround from 2019 when net profits stood at just EGP 16 million ...